26
|
Imafuku K, Hata H, Kitamura S, Yanagi T, Shimizu H. Ultrasonographic findings can identify 'pseudoprogression' under nivolumab therapy. Br J Dermatol 2017; 177:1726-1731. [PMID: 27873302 DOI: 10.1111/bjd.15198] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2016] [Indexed: 12/18/2022]
Abstract
'Pseudoprogression' is often seen in patients with melanomas who are treated with immune checkpoint inhibitors such as nivolumab or ipilimumab. We sometimes evaluate metastatic lesions by imaging tests such as computed tomography (CT) or positron emission tomography-CT. 'Pseudoprogression' usually occurs upon the initial administration, which may make it difficult for the physician to determine the disease condition. In our two cases of metastatic melanoma treated with nivolumab (antiprogrammed cell death-1 antibody), we examined the ultrasonography (US) of target lesions that could be accessed from the body surface, such as those of the regional lymph node or subcutaneous metastasis. In both cases, the US revealed a lesion approximately 10% greater in size after 40-50 days of nivolumab administration, even though the blood flow inside the tumour was reduced by about 20% within 50 days. From about 100 days after blood flow reduction was detected by US, the tumours began to decrease in size. However, contrast CT was unable to detect the association between tumour size and tumour blood flow. The present cases suggest that US could be a powerful tool for differentiating between 'pseudoprogression' and real progressive disease in patients treated with cancer immunotherapies such as those involving immune checkpoint inhibitors. The misdiagnosis of progressive disease can lead to unnecessary alterations to the current treatment. Therefore, the US findings in our study could be clinically useful and educational for physicians.
Collapse
|
27
|
Yanagi T, Hata H, Homma E, Kitamura S, Imafuku K, Shimizu H. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis. Clin Exp Dermatol 2017. [PMID: 28649738 DOI: 10.1111/ced.13179] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Interferon (IFN)-alfa as an adjuvant therapy has been found to improve relapse-free survival in patients with malignant melanoma (MM). However, the efficacy of IFN-beta has not been studied in detail. This study evaluated the contribution of adjuvant IFN-beta therapy to improvements in the prognosis of patients with MM. We reviewed 63 patients with resected stage II/III primary MM at our institution. Of these, 36 had been treated with IFN-beta adjuvant therapy (subcutaneous injection, 3 × 106 IU/day, 10 days), while 27 patients had undergone observation alone. In comparisons of all patients (stage II/III), overall survival and relapse-free survival were significantly better in the IFN-beta group than in the observation group (P < 0.001 for both). The 75-month overall survival rate was 41.2% in the observation group and 68.7% in the IFN-beta group. Adjuvant therapy with IFN-beta may become a new treatment option for patients with stage II/III MM.
Collapse
|
28
|
Sanada T, Hata H, Sato K, Imafuku K, Kitamura S, Yanagi T, Nomura T, Shimizu H. Usefulness of dermoscopy in distinguishing benign lesions from angiosarcoma. Clin Exp Dermatol 2017; 42:676-678. [PMID: 28543107 DOI: 10.1111/ced.13141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/24/2016] [Indexed: 11/30/2022]
|
29
|
Imafuku K, Hata H, Yanagi T, Kitamura S, Inamura-Takashima Y, Nishimura M, Kitamura S, Moriwaki S, Shimizu H. Multiple skin cancers in patients with mycosis fungoides after long-term ultraviolet phototherapy. Clin Exp Dermatol 2017; 42:523-526. [PMID: 28543586 DOI: 10.1111/ced.13121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2016] [Indexed: 11/28/2022]
Abstract
Phototherapy is a useful noninvasive therapy, but it can induce cutaneous malignant tumours, including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). We report on a 79-year-old man who had long-standing mycosis fungoides for 40 years, which had been treated with psoralen ultraviolet A therapy for 37 years at a dose of approximately 5000 J/cm2 . Approximately 6 years before presentation, numerous types of cutaneous malignancies, including actinic keratosis, BCC and SCC, had begun to develop all over the patient's body. We hypothesized that he was experiencing a pathogenesis similar to patients with xeroderma pigmentosum (XP), and we therefore assessed his DNA repair capacity. Based on these investigations, the patient was eventually diagnosed as non-XP, even though we detected that his DNA repair capacity was slightly lower than that of normal controls, which may have led to the skin cancers. We speculate that multiple skin malignancies can be induced by long-term phototherapy in patients with slightly impaired DNA repair capacity.
Collapse
|
30
|
Takahashi K, Yanagi T, Imafuku K, Kitamura S, Inamura-Takashima Y, Yamaguchi Y, Hata H, Shimizu H. Ultrasonographic features of intravascular fasciitis: case report and review of the literature. J Eur Acad Dermatol Venereol 2017; 31:e457-e459. [PMID: 28426899 DOI: 10.1111/jdv.14293] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
31
|
Kuroda K, Sunami H, Matsumoto Y, Nakajima S, Sato T, Seguchi O, Hata H, Yanase M, Fujita T, Kobayashi J, Fukushima N. Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Heart Transplant Recipients With Transplant Coronary Arterial Vasculopathy. Transplant Proc 2017; 49:130-134. [PMID: 28104120 DOI: 10.1016/j.transproceed.2016.11.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Transplant coronary arterial vasculopathy (TCAV) is a major cause of death after heart transplantation (HTx). Palliative coronary revascularization has been attempted in patients with severe TCAV; however, the outcome has not been fully elucidated. METHODS Ninety-six patients who were treated after HTx at our institute between 1999 and 2015 were screened for TCAV. TCAV was defined as >70% stenosis on coronary angiography (CAG) or a maximal intimal thickness of >0.5 mm in the right or left coronary arteries on intracoronary ultrasonography (IVUS). In the present study, the outcomes of patients with severe TCAV who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were investigated. RESULTS TCAV containing donor-transmitted atherosclerosis was cumulatively found in 69 patients (71.9% of the total; mean age, 34.6 ± 13.1 years; 52 men; mean follow-up duration, 83.0 ± 60.4 months). Five (7.2%) and 64 (92.8%) of the 69 patients were diagnosed as having TCAV by use of CAG and IVUS, respectively. All 5 patients diagnosed by with the use of CAG underwent coronary revascularization between 1 and 236 months after HTx. Three patients underwent PCI with drug-eluting stents, with a primary success rate of 100%. No angiographic restenosis occurred in 2 patients at 31 and 36 months after PCI, respectively. Meanwhile, 2 patients underwent CABG. No peri-operative complications occurred, and all grafts were patent as assessed by use of CAG at 34 and 5 months after CABG. CONCLUSIONS Coronary revascularization was feasible and effective for severe TCAV with middle-term follow-up.
Collapse
|
32
|
Verheyen E, Abila R, Akoll P, Albertson C, Antunes D, Banda T, Bills R, Bulirani A, Manda AC, Cohen AS, Cunha-Saraiva F, Derycke S, Donohue I, Du M, Dudu AM, Egger B, Fritzsche K, Frommen JG, Gante HF, Genner MJ, Härer A, Hata H, Irvine K, Mwapu PI, de Bisthoven LJ, Jungwirth A, Kaleme P, Katongo C, Kéver L, Koblmüller S, Konings A, Lamboj A, Lemmel-Schaedelin F, Schiaffino GM, Martens K, Mulungula PM, Meyer A, More HL, Musilova Z, Bukinga FM, Muzumani R, Ntakimazi G, Okello W, Phiri H, Pialek L, Plisnier PD, Raeymaekers JAM, Rajkov J, Rican O, Roberts R, Salzburger W, Schoen I, Sefc KM, Singh P, Skelton P, Snoeks J, Schneider K, Sturmbauer C, Svardal H, Svensson O, Dowdall JT, Turner GF, Tyers A, van Rijssel JC, Van Steenberge M, Vanhove MPM, Weber AT, Weyl O, Ziegelbecker A, Zimmermann H. Oil extraction imperils Africa's Great Lakes. Science 2017; 354:561-562. [PMID: 27811261 DOI: 10.1126/science.aal1722] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
Ueno N, Nishimura N, Ueno S, Endo S, Tatetsu H, Hirata S, Hata H, Matsuoka M, Mitsuya H, Okuno Y. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene 2017; 36:4481-4497. [PMID: 28368411 DOI: 10.1038/onc.2017.79] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 02/09/2017] [Accepted: 02/26/2017] [Indexed: 12/13/2022]
Abstract
We previously reported that PU.1 is downregulated in the majority of myeloma cell lines and primary myeloma cells of certain myeloma patients, and conditional expression of PU.1 in such myeloma cell lines induced cell cycle arrest and apoptosis. We found downregulation of IRF4 protein in the U266 myeloma cell line following induction of PU.1. Previous studies reported that knockdown of IRF4 in myeloma cell lines induces apoptosis, prompting us to further investigate the role of IRF4 downregulation in PU.1-induced cell cycle arrest and apoptosis in myeloma cells. PU.1 induced downregulation of IRF4 at the protein level, cell cycle arrest and apoptosis in six myeloma cell lines. Chromatin immunoprecipitation (ChIP) revealed that PU.1 directly binds to the IRF4 promoter, whereas a reporter assay showed that PU.1 may suppress IRF4 promoter activity. Stable expression of IRF4 in myeloma cells expressing PU.1 partially rescued the cells from apoptosis induced by PU.1. As it was reported that IRF4 directly binds to the IRF7 promoter and downregulates its expression in activated B cell-like subtype of diffuse large B cell lymphoma cells, we performed ChIP assays and found that IRF4 directly binds the IRF7 promoter in myeloma cells. It is known that IRF7 positively upregulates interferon-β (IFNβ) and induces apoptosis in many cell types. Binding of IRF4 to the IRF7 promoter decreased following PU.1 induction, accompanied by downregulation of IRF4 protein expression. Knockdown of IRF7 protected PU.1-expressing myeloma cells from apoptosis. Furthermore, IFNβ, which is a downstream target of IRF7, was upregulated in myeloma cells along with IRF7 after PU.1 induction. Finally, we evaluated the mRNA expression levels of PU.1, IRF4 and IRF7 in primary myeloma cells from patients and found that PU.1 and IRF7 were strongly downregulated in contrast to the high expression levels of IRF4. These data strongly suggest that PU.1-induced apoptosis in myeloma cells is associated with IRF4 downregulation and subsequent IRF7 upregulation.
Collapse
|
34
|
Kuroda K, Kumai Y, Sunami H, Nakajima S, Sato T, Seguchi O, Yanase M, Matsumoto Y, Hata H, Fujita T, Kobayashi J, Fukushima N. Ventricular Assist Device Support for Ischemic Cardiomyopathy: A Single-Center Experience in Japan. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
35
|
Yamaguchi Y, Yanagi T, Imafuku K, Kitamura S, Hata H, Nishihara H, Shimizu H. A case of linear basal cell carcinoma: evaluation of proliferative activity by immunohistochemical staining of PCTAIRE1 and p27. J Eur Acad Dermatol Venereol 2017; 31:e359-e362. [PMID: 28168733 DOI: 10.1111/jdv.14159] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Hata H, Motomura H. A new species of anchovy, Encrasicholina auster (Clupeiformes: Engraulidae) from Fiji, southwestern Pacific Ocean. NEW ZEALAND JOURNAL OF ZOOLOGY 2017. [DOI: 10.1080/03014223.2016.1268177] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Hypothyroidism associated with nivolumab treatment of unresectable malignant melanoma. Clin Exp Dermatol 2017; 42:217-218. [PMID: 28052364 DOI: 10.1111/ced.13028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2016] [Indexed: 12/26/2022]
|
38
|
Saito S, Hata H, Inamura Y, Kitamura S, Yanagi T, Shimizu H. Vulvar basal cell carcinoma with adhesion of the labia majora and minora. Clin Exp Dermatol 2016; 42:92-93. [PMID: 27917514 DOI: 10.1111/ced.12956] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2016] [Indexed: 11/30/2022]
|
39
|
Imafuku K, Yoshino K, Ishiwata K, Otobe S, Tsuboi S, Ohara K, Hata H. A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab. J Eur Acad Dermatol Venereol 2016; 30:e227-e229. [DOI: 10.1111/jdv.13561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Kawanishi R, Sogabe A, Nishimoto R, Hata H. Spatial variation in the parasitic isopod load of the Japanese halfbeak in western Japan. DISEASES OF AQUATIC ORGANISMS 2016; 122:13-19. [PMID: 27901500 DOI: 10.3354/dao03064] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Cymothoid isopods (family Cymothoidae) are commonly found parasitizing diverse fishes, including commercial species. However, the effects of these parasites on host body condition are still poorly known. Here we investigated the spatial variation of the effects of parasite infection on host body condition, using the parasitic load of the cymothoid Mothocya parvostis on the Japanese halfbeak Hyporhamphus sajori at 4 sampling sites in western Japan. M. parvostis prevalence at each site (41.6-74.4%) was higher than that known for other fish host-cymothoid systems (usually less than 30%). The number of isopods in infected hosts, the reproductive status of female isopods (i.e. ovigerous/non-ovigerous), and the body size of female and male isopods relative to the size of their hosts were not significantly different among sites. However, at the site where human activity was most intense, M. parvostis infection had a significantly negative effect on host body condition. These results suggest that the effect of cymothoid infection on host body condition might be benign under natural conditions but becomes detrimental in habitats that are unsuitable for the host, such as highly human-impacted areas.
Collapse
|
41
|
Kitamura S, Hata H, Inamura Y, Imafuku K, Muramatsu K, Yanagi T, Shimizu H. Lessons from 20 cases of digit malignant melanoma. J Eur Acad Dermatol Venereol 2016; 30:e161-e163. [PMID: 26537559 DOI: 10.1111/jdv.13467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
42
|
Imafuku K, Yoshino K, Ymaguchi K, Tsuboi S, Ohara K, Hata H. Nivolumab therapy before vemurafenib administration induces a severe skin rash. J Eur Acad Dermatol Venereol 2016; 31:e169-e171. [PMID: 27546003 DOI: 10.1111/jdv.13892] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
43
|
Stigloher J, Decker M, Körner HS, Tanabe K, Moriyama T, Taniguchi T, Hata H, Madami M, Gubbiotti G, Kobayashi K, Ono T, Back CH. Snell's Law for Spin Waves. PHYSICAL REVIEW LETTERS 2016; 117:037204. [PMID: 27472134 DOI: 10.1103/physrevlett.117.037204] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Indexed: 06/06/2023]
Abstract
We report the experimental observation of Snell's law for magnetostatic spin waves in thin ferromagnetic Permalloy films by imaging incident, refracted, and reflected waves. We use a thickness step as the interface between two media with different dispersion relations. Since the dispersion relation for magnetostatic waves in thin ferromagnetic films is anisotropic, deviations from the isotropic Snell's law known in optics are observed for incidence angles larger than 25° with respect to the interface normal between the two magnetic media. Furthermore, we can show that the thickness step modifies the wavelength and the amplitude of the incident waves. Our findings open up a new way of spin wave steering for magnonic applications.
Collapse
|
44
|
Imafuku K, Hata H, Inamura Y, Kitamura S, Natsuga K, Iwata H, Shimizu H. Verrucous hyperplasia associated with neuropathy from schistorrhachis. J Eur Acad Dermatol Venereol 2016; 30:876-8. [PMID: 25715672 DOI: 10.1111/jdv.13042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Nakajima S, Okada N, Kuroda K, Hisamatsu E, Sunami H, Sato T, Seguchi O, Yanase M, Hata H, Fujita T, Fukushima N, Kobayashi J, Nakatani T. The Role of Biventricular Assist Device on Patients with Multiorgan Failure Due to Fulminant Myocarditis: Single-Center Experience. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.1146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
46
|
Watanabe T, Seguchi O, Yanase M, Fujita T, Sato T, Sunami H, Nakajima S, Nishimura K, Hisamatsu E, Kuroda K, Okada N, Wada K, Hata H, Ishibashi-Ueda H, Miyamoto Y, Kobayashi J, Fukushima N, Nakatani T. Relationship Between Brachial Artery Flow-Mediated Dilation and Clinical Characteristics of Heart Transplant Recipients. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
47
|
Hata H, Fujita T, Ishibashi-Ueda H, Fukushima N, Nakatani T, Kobayashi J. Primary Graft Dysfunction after Heart Transplantation with High Frequency of Marginal Donor Hearts. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
48
|
Sato T, Seguchi O, Kanaumi Y, Yanase M, Okada N, Kuroda K, Hisamatsu E, Sunami H, Nakajima S, Hata H, Fujita T, Ishibashi-Ueda H, Fukushima N, Kobayashi J, Nakatani T. Clinical Implication of Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: Do We Really Have to Care All the DSA Positive Patients? J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
49
|
Hisamatsu E, Seguchi O, Okada N, Kuroda K, Sunami H, Nakajima S, Sato T, Hata H, Yanase M, Fujita T, Fukushima N, Kobayashi J, Nakatani T. Gynecological Complications in Female Patients with Left Ventricular Assist Device Support. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
|